Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVATRAN
2024-513808-34-00Phase 3Completed
- Sponsor
- CHRU Nancy
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of eplerenone in kidney transplant, arteriosclerosis, Vasculopathy and 1 more (2 arms), sponsored by CHRU Nancy. Primary endpoint: Evolution of pulse wave velocity (PWV). Started Aug 2024; status: completed.
02
Drugs
eplerenone
03
Conditions
kidney transplantarteriosclerosisVasculopathyhypertension (HTN)
Beyond the preview
Go deeper on 2024-513808-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513808-34-00.